GTNF/Polosa: “A rigorous scientific approach to Harm Reduction is a resource”
A group of Harm Reduction experts and scientists discussed the latest news on THR during the virtual meeting GTNF In Focus: THR 2021
CoEHAR among the contributors of the Beating Cancer Plan
The Center of Excellence for the Acceleration of Harm Reduction (CoEHAR) is among the contributors for the drafting of the BECA Report by the Special Committee on Cancer of the European Parliament
Thursday 22th of April, CoEHAR organizes the kick-off online meeting of the Smile Study
The Center of Excellence for the Acceleration of Harm Reduction (CoEHAR) is pleased to present the "Smile Study", a new research project committed to reducing the damage caused by smoking…
Replica (CoEHAR): is there any correlation between Covid-19 and Harm Reduction?
A new study by CoEHAR, the "Role of Cigarette Smoke on Angiotensin-Converting Enzyme-2 Protein Membrane Expression in Bronchial Epithelial Cells Using an Air-Liquid Interface Model" investigates the molecular mechanisms that regulate the expression of the ACE2 enzyme, involved in Covid-19 infection
Replica Project: a new study sets quality standards for the storage conditions of nicotine samples
The new study by CoEHAR, "Nicotine dosimetry and stability in cambridge filter PADs (CFPs) following different smoking regime protocols and storage conditions", provided new guidelines for future multicentric studies in the low-risk products
COVID-19 and the human body: nicotine as a “controller” of the molecular expression of ACE-2
Nicotine is a protective shield against the insurgence of severe symptoms of COVID-19. This is what emerged with the new study by CoEHAR
CoEHAR’s study confirms beneficial effects of ecig on copd smokers
CoEHAR's researchers have just published the longest clinical follow-up of E-cigarette users ever reported. The study “COPD smokers who switched to e-cigarettes: health outcomes at 5-year follow up” explores the long term effects of E-cigarette use in patients with chronic obstructive pulmonary disease (COPD) and confirms that regular use can ameliorate objective and subjective COPD and is long lasting
Expert Panel to Discuss Diversity and Harm Reduction in Global Tobacco Control Policy Virtual Webinar Sessions Sept.30 and Oct.1
Reflecting on the 15th Year of the World Health Organization’s Framework Convention on Tobacco Control (WHO FCTC), two international expert panel sessions featuring leading academics, researchers and NGO principals will cover the key questions and challenges facing policymakers in achieving more effective and equitable implementation globally
Gtfn 2020: Sustainability and Innovation are crucially for the future of Tobacco Harm Reduction
What are the best practises the tobacco industry should follow to achieve a sustainable change through the innovation and regulation? This was the question that this year’s Global Tobacco and Nicotine Forum, GTFN 2020, focused on
CoEHAR research set new guidelines for the dosage of nicotine in liquids
CoEHAR researchers call out the standardization of research methodologies on electronic cigarettes as a milestone for the effectiveness of the procedures to quit smoking
